CN Mobile Logo


Breast Cancer

Breast Cancer

Using a 70-gene signature test could identify many women with early-stage breast cancer considered to be at high clinical risk who do not actually need chemotherapy.

Breast density and breast cancer risk can help guide mammography screening recommendations for women older than age 50 years.

­Three medical organizations including ASCO have issued a guideline on margins in breast conserving surgery for patients with ductal carcinoma in situ.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.

Bone metastases are common in advanced breast cancer, and may be associated with serious morbidity, including fractures, pain, nerve compression, and hypercalcemia. Through optimum multidisciplinary management and the use of bone-targeted treatments, patients with advanced breast cancer have experienced a major reduction in skeletal complications, less bone pain, and an improved quality of life.

It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.

Women with ER-positive metastatic breast cancer previously treated with an aromatase inhibitor have worse survival outcomes if their tumor harbors one of two estrogen receptor mutations.


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.